Sorafenib in the treatment of radioiodine-refractory differentiated thyroid cancer: A meta-analysis

Endocrine-Related Cancer

Volumn 21, Issue 2, 2014, Pages 253-261

  Shen, Chen Tian ^a   Qiu, Zhong Ling ^a   Luo, Quan Yong ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Differentiated thyroid cancer; Meta analysis; Molecular targeted therapy; Sorafenib; Tyrosine kinase inhibitors

Indexed keywords

SORAFENIB;

ANGIONEUROTIC EDEMA; ARTICLE; BRAIN HEMORRHAGE; COST; DIARRHEA; DIFFERENTIATED THYROID CANCER; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; EMBASE; FATIGUE; HAND FOOT SYNDROME; HEART ARREST; HUMAN; HYPERTENSION; LUNG SMALL CELL CANCER; MEDLINE; META ANALYSIS; RADIOIODINE REFRACTORY DIFFERENTIATED THYROID CANCER; RASH; TONGUE CARCINOMA; TREATMENT RESPONSE; WEIGHT REDUCTION;

DIFFERENTIATED THYROID CANCER; META-ANALYSIS; MOLECULAR TARGETED THERAPY; SORAFENIB; TYROSINE KINASE INHIBITORS;

ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; HUMANS; IODINE RADIOISOTOPES; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; THYROID NEOPLASMS;

EID: 84899080821     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-13-0438     Document Type: Article

References (36)

1. Ahmed M, Barbachano Y, Riddell A, Hickey J, Newbold KL, Viros A, Harrington KJ, Marais R & Nutting CM 2011 Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population. European Journal of Endocrinology 165 315-322. (doi:10. 1530/EJE-11-0129)
2. Ain KB, Lee C & Williams KD 2007 Phase II trial of thalidomide for therapy of radioiodine-unresponsive and rapidly progressive thyroid carcinomas. Thyroid 17 663-670. (doi:10.1089/thy.2006.0289)
3. Albarel F, Conte-Devolx B & Oliver C 2012 From nodule to differentiated thyroid carcinoma: contributions of molecular analysis in 2012. Annales d'Endocrinologie 73 155-164. (doi:10.1016/j.ando.2012.03.002)
4. Anderson RT, Linnehan JE, Tongbram V, Keating K & Wirth LJ 2013 Clinical, safety, and economic evidence in radioactive iodine-refractory differentiated thyroid cancer: a systematic literature review. Thyroid 23 392-407. (doi:10.1089/thy.2012.0520)
5. Berlin JA 1995 Invited commentary: benefits of heterogeneity in metaanalysis of data from epidemiologic studies. American Journal of Epidemiology 142 383-387.
6. Bible KC, Suman VJ, Molina JR, Smallridge RC, Maples WJ, Menefee ME, Rubin J, Sideras K, Morris JC III, McIver B et al. 2010 Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: Results of a phase 2 consortium study. Lancet Oncology 11 962-972. (doi:10.1016/S1470-2045(10)70203-5)
7. Brose MS, Smit J, Capdevila J, Elisei R, Nutting C, Pitoia F, Robinson B, Schlumberger M, Shong YK & Takami H 2012 Regional approaches to the management of patients with advanced, radioactive iodine-refractory differentiated thyroid carcinoma. Expert Review of Anticancer Therapy 12 1137-1147. (doi:10.1586/era.12.96)
8. Brose MS, Nutting CM, Jarzab B, Elisei R, Siena S, Bastholt L, de la Fouchardiere C, Pacini F, Paschke R, Shong YK et al. 2013 Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer: the phase III DECISION trial. Journal of Clinical Oncology 31 (supplement; abstract 4).
9. Busaidy NL & Cabanillas ME 2012 Differentiated thyroid cancer: management of patients with radioiodine nonresponsive disease. Journal of Thyroid Research 2012 618985. (doi:10.1155/2012/618985)
10. Capdevila J, Iglesias L, Halperin I, Segura A, Martínez-Trufero J, Vaz MA, Corral J, Obiols G, Grande E, Grau JJ et al. 2012 Sorafenib in metastatic thyroid cancer. Endocrine-Related Cancer 19 209-216. (doi:10.1530/ERC-11-0351)
11. Carr LL, Mankoff DA, Goulart BH, Eaton KD, Capell PT, Kell EM, Bauman JE & Martins RG 2010 Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clinical Cancer Research 16 5260-5268. (doi:10.1158/1078-0432.CCR-10-0994)
12. Chen L, Shen Y, Luo Q, Yu Y, Lu H & Zhu R 2011 Response to sorafenib at a low dose in patients with radioiodine-refractory pulmonary metastases from papillary thyroid carcinoma. Thyroid 21 119-124. (doi:10.1089/thy.2010.0199)
13. Copas J & Shi JQ 2000 Meta-analysis, funnel plots and sensitivity analysis. Biostatistics 1 247-262. (doi:10.1093/biostatistics/1.3.247)
14. Dadu R & Cabanillas ME 2012 Optimizing therapy for radioactive iodine-refractory differentiated thyroid cancer: current state of the art and future directions. Minerva Endocrinologica 37 335-356.
15. DerSimonian R & Laird N 1986 Meta-analysis in clinical trials. Controlled Clinical Trials 7 177-188. (doi:10.1016/0197-2456(86)90046-2)
16. Duntas LH & Bernardini R 2010 Sorafenib: rays of hope in thyroid cancer. Thyroid 20 1351-1358. (doi:10.1089/thy.2010.0056)
17. Eheman C, Henley SJ, Ballard-Barbash R, Jacobs EJ, Schymura MJ, Noone AM, Pan L, Anderson RN, Fulton JE, Kohler BA et al. 2012 Annual Report to the Nation on the status of cancer, 1975-2008, featuring cancers associated with excess weight and lack of sufficient physical activity. Cancer 118 2338-2366. (doi:10.1002/cncr.27514)
18. Gupta-Abramson V, Troxel AB, Nellore A, Puttaswamy K, Redlinger M, Ransone K, Mandel SJ, Flaherty KT, Loevner LA, O'Dwyer PJ et al. 2008 Phase II trial of sorafenib in advanced thyroid cancer. Journal of Clinical Oncology 26 4714-4719. (doi:10.1200/JCO.2008.16.3279)
19. Ho AL, Grewal RK, Leboeuf R, Sherman EJ, Pfister DG, Deandreis D, Pentlow KS, Zanzonico PB, Haque S, Gavane S et al. 2013 Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. New England Journal of Medicine 368 623-632. (doi:10.1056/NEJMoa1209288)
20. 2 index? Psychological Methods 11 193-206. (doi:10.1037/1082-989X. 11.2.193)
21. Kebebew E, Lindsay S, Clark OH, Woeber KA, Hawkins R & Greenspan FS 2009 Results of rosiglitazone therapy in patients with thyroglobulin-positive and radioiodine-negative advanced differentiated thyroid cancer. Thyroid 19 953-956. (doi:10.1089/thy.2008.0371)
22. Kloos RT, Ringel MD, Knopp MV, Hall NC, King M, Stevens R, Liang J, Wakely PE Jr, Vasko VV, Saji M et al. 2009 Phase II trial of sorafenib in metastatic thyroid cancer. Journal of Clinical Oncology 27 1675-1684. (doi:10.1200/JCO.2008.18.2717)
23. Kojic KL, Kojic SL & Wiseman SM 2012 Differentiated thyroid cancers: a comprehensive review of novel targeted therapies. Expert Review of Anticancer Therapy 12 345-357. (doi:10.1586/era.12.8)
24. Leboulleux S, Bastholt L, Krause T, de laFouchardiere C, Tennvall J, Awada A, Gómez JM, Bonichon F, Leenhardt L, Soufflet C et al. 2012 Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial. Lancet Oncology 13 897-905. (doi:10.1016/S1470-2045(12)70335-2)
25. Marotta V, Ramundo V, Camera L, Del Prete M, Fonti R, Esposito R, Palmieri G, Salvatore M, Vitale M, Colao A et al. 2013 Sorafenib in advanced iodine-refractory differentiated thyroid cancer: efficacy, safety and exploratory analysis of role of serum thyroglobulin and FDG-PET. Clinical Endocrinology 78 760-767. (doi:10.1111/cen.12057)
26. Moher D, Liberati A, Tetzlaff J & Altman DG 2009 Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement. Journal of Clinical Epidemiology 62 1006-1012. (doi:10.1016/j.jclinepi. 2009.06.005)
27. Mrozek E, Kloos RT, Ringel MD, Kresty L, Snider P, Arbogast D, Kies M, Munden R, Busaidy N, Klein MJ et al. 2006 Phase II study of celecoxib in metastatic differentiated thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 91 2201-2204. (doi:10.1210/jc.2005-2498)
28. Perez CA, Arango BA, Velez M, Raez LE & Santos ES 2012 Emerging role of multikinase inhibitors for refractory thyroid cancer. Biologics 6 257-265. (doi:10.2147/BTT.S24465)
29. Regalbuto C, Frasca F, Pellegriti G, Malandrino P, Marturano I, Di Carlo I & Pezzino V 2012 Update on thyroid cancer treatment. Future Oncology 8 1331-1348. (doi:10.2217/fon.12.123)
30. Schneider TC, Abdulrahman RM, Corssmit EP, Morreau H, Smit WA & Kapiteijn E 2012 Long-term analysis of the efficacy and tolerability of sorafenib in advanced radio-iodine refractory differentiated thyroid carcinoma: final results of a phase II trial. European Journal of Endocrinology 167 643-650. (doi:10.1530/EJE-12-0405)
31. Sherman SI 2010 Cytotoxic chemotherapy for differentiated thyroid carcinoma. Clinical Oncology 22 464-468. (doi:10.1016/j.clon.2010.03.014)
32. Sherman SI, Wirth LJ, Droz JP, Hofmann M, Bastholt L, Martins RG, Licitra L, Eschenberg MJ, Sun YN, Juan T et al. 2008 Motesanib diphosphate in progressive differentiated thyroid cancer. New England Journal of Medicine 359 31-42. (doi:10.1056/NEJMoa075853)
33. Siegel R, Naishadham D & Jemal A 2013 Cancer statistics, 2013. CA: A Cancer Journal for Clinicians 63 11-30. (doi:10.3322/caac.21166)
34. Smith KJ, Haley H, Hamza S & Skelton HG 2009 Eruptive keratoacanthoma-type squamous cell carcinomas in patients taking sorafenib for the treatment of solid tumors. Dermatologic Surgery 35 1766-1770. (doi:10.1111/j.1524-4725.2009.01289.x)
35. Wilhelm S, Carter C, Lynch M, Lowinger T, Dumas J, Smith RA, Schwartz B, Simantov R & Kelley S 2006 Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nature Reviews. Drug Discovery 5 835-844. (doi:10.1038/nrd2130)
36. Woyach JA, Kloos RT, Ringel MD, Arbogast D, Collamore M, Zwiebel JA, Grever M, Villalona-Calero M & Shah MH 2009 Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 94 164-170. (doi:10.1210/jc.2008-1631)